摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

别嘌呤醇核糖苷 | 16220-07-8

中文名称
别嘌呤醇核糖苷
中文别名
——
英文名称
allopurinol riboside
英文别名
Allopurinol Riboside;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
别嘌呤醇核糖苷化学式
CAS
16220-07-8
化学式
C10H12N4O5
mdl
——
分子量
268.229
InChiKey
KFQUAMTWOJHPEJ-DAGMQNCNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    715.0±60.0 °C(Predicted)
  • 密度:
    2.08±0.1 g/cm3(Predicted)
  • 溶解度:
    DMSO:5.0(最大浓度 mg/mL);18.64(最大浓度 mM)PBS (pH 7.2):5.0(最大浓度 mg/mL);18.64(最大浓度 mM)
  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    -2.3
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    129
  • 氢给体数:
    4
  • 氢受体数:
    7

安全信息

  • WGK Germany:
    3

SDS

SDS:530f2a1b581d5b5ba868768b8fb4746f
查看

制备方法与用途

生物活性

Allopurinol riboside 是别嘌呤醇的代谢物,能有效抑制寄生虫。

靶点

Human Endogenous Metabolite


体外研究

Allopurinol-riboside 竞争性地抑制嘌呤核苷磷酸化酶对次黄嘌呤的作用,Ki值为277 μM。在PHA和Con A诱导的淋巴细胞转化中,allopurinol-riboside 以浓度依赖的方式显著抑制了淋巴细胞增殖。当使用LPS作为刺激因子时,Allopurinol riboside 对淋巴细胞增殖的抑制作用较为不明显。Allopurinol riboside 不会抑制体液免疫。它是一种治疗利什曼病和美国锥虫病的实验性药物,因为一系列酶(类似于人类嘌呤回收中的那些酶)将它转化为4-氨基嘌唑嘧啶核苷三磷酸,这是一种细胞毒性产物。Allopurinol riboside 对人体的选择性毒性在于它在人类中不被相应的酶代谢。


体内研究

Allopurinol riboside 在给药后1.6小时达到血浆峰值,并且半衰期为3小时,在治疗范围内具有稳定的浓度。口服给药后,Allopurinol riboside 血浆中的低水平是由于吸收不完全和快速的肾清除所致。Probenecid 可减少其在肾脏的清除率,延长血浆中Allopurinol riboside 的半衰期,并使其在血浆中的浓度增加三倍。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    别嘌呤醇核糖苷吡啶silver nitrateN,N-二异丙基乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 52.25h, 生成 1-(β-D-ribofuranosyl)-5'-O-(4,4'-dimethyloxytrityl)-2'-O-(tbutyldimethylsilyl)-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
    参考文献:
    名称:
    TLR8激活和鸟嘌呤类似物在RNA中的抑制作用:官能团和链长的重要性
    摘要:
    Toll样受体8(TLR8)是人类先天免疫系统的重要组成部分,可识别单链RNA(ssRNA)。与ssRNA结合的TLR8的最新X射线晶体结构揭示了以前无法识别的5'-UpG-3'二核苷酸结合位点。在这里,我们使用原子诱变策略与细胞TLR8激活检测相结合,以探查在RNA介导的受体激动和拮抗作用中鸟嘌呤碱基上存在的特定官能团的重要性。包含7-脱氮鸟苷,2-氨基嘌呤和肌苷的RNA类似物的结果证实了鸟嘌呤N7,O6和N2在TLR8激活中的重要性。然而,这些RNA各自保留了TLR8拮抗活性。由新型亚磷酰胺制备了含7-脱氮基8-氮杂肌苷(7d8aI)的RNA,并发现它是一种比含鸟苷的RNA弱的TLR8激活剂。但是,含7d8aI的RNA也保留了TLR8拮抗活性,这表明鸟嘌呤上多个TLR8 H结合位点的去除不足以阻断含鸟嘌呤的RNA对TLR8的拮抗作用。我们还确定了对TLR8激活和拮抗的寡核糖核苷酸长度的
    DOI:
    10.1016/j.bmc.2017.11.020
  • 作为产物:
    描述:
    7-甲基鸟苷碘化物potassium dihydrogenphosphate 、 purine nucleoside phosphorylase 作用下, 以 aq. buffer 为溶剂, 反应 121.0h, 生成 别嘌呤醇核糖苷
    参考文献:
    名称:
    酶法合成2-脱氧核糖1-磷酸和核糖1磷酸及随后的核苷制备
    摘要:
    我们提供了一种从7-Me-Guo和7-Me-dGuo制备Rib-p和dRib-p的新型酶促方法。在存在PNP的情况下,7-Me-Guo和7-Me-dGuo的几乎不可逆的磷酸分解可确保起始核苷定量转化为异构纯α-Rib-p和α-dRib-p。分离和纯化后,Rib-p和dRib-p的收率为74–96%。
    DOI:
    10.1002/ejoc.201901454
点击查看最新优质反应信息

文献信息

  • Recognition of Artificial Nucleobases by<i>E. coli</i>Purine Nucleoside Phosphorylase versus its Ser90Ala Mutant in the Synthesis of Base-Modified Nucleosides
    作者:Ilja V. Fateev、Maria I. Kharitonova、Konstantin V. Antonov、Irina D. Konstantinova、Vasily N. Stepanenko、Roman S. Esipov、Frank Seela、Kartik W. Temburnikar、Katherine L. Seley-Radtke、Vladimir A. Stepchenko、Yuri A. Sokolov、Anatoly I. Miroshnikov、Igor A. Mikhailopulo
    DOI:10.1002/chem.201501334
    日期:2015.9.14
    mechanism of recognition by the wild‐type (WT) E. coli purine nucleoside phosphorylase (PNP) versus its Ser90Ala mutant. The results were analyzed from viewpoint of the role of the Ser90 residue and the structural features of the bases. It was found that the Ser90 residue of the PNP 1) plays an important role in the binding and activation of 8‐aza‐7‐deazapurines in the synthesis of their nucleosides, 2) participates
    广泛的天然嘌呤类似物用作探针,以评估野生型(WT)大肠杆菌嘌呤核苷磷酸化酶(PNP)与其Ser90Ala突变体的识别机制。从Ser90残基的作用和碱基的结构特征的角度分析了结果。发现PNP的Ser90残基在其核苷合成中的8-氮杂-7-脱氮嘌呤的结合和活化中起重要作用; 2)参与α - D-戊呋喃糖-1的结合。在PNP的催化位点处的磷酸,以及3)催化中间形成的2-deoxy-α- D的去磷酸化反式2-脱氧核糖基化反应中的核糖呋喃糖-1-磷酸。5-氮杂-7-脱氮鸟嘌呤对两种酶均表现出优异的底物活性,8-氨基-7-硫杂鸟嘌呤和2-氨基苯并噻唑对两种酶均无底物活性。相反,苯并咪唑和苯并恶唑的2-氨基衍生物是底物,分别被转化为N1-糖苷和不寻常的N2-糖苷。9-Deaza-5-碘黄嘌呤对野生型大肠杆菌PNP具有中等抑制活性,而9-deazaxanthine及其2'-脱氧核糖苷是弱抑制剂。
  • Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 2. Synthesis and activity of some nucleosides of 4-(alkylamino)-1H-pyrazolo[3,4-d]pyrimidines
    作者:Janet L. Rideout、Thomas A. Krenitsky、George W. Koszalka、Naomi K. Cohn、Esther Y. Chao、Gertrude B. Elion、Victoria S. Latter、Raymond B. Williams
    DOI:10.1021/jm00351a007
    日期:1982.9
    A series of 4-(alkylamino)-1-beta-D-ribofuranosyl-1H-pyrazolo[3, 4-d]pyrimidines was synthesized by enzymatic and chemical methods. On the basis of the previous finding that 4-(alkylthio)-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidines were effective anticoccidial agents, this series was examined for efficacy against Eimera tenella in chicks. The most active anticoccidial agent in the present
    通过酶和化学方法合成了一系列的4-(烷基氨基)-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶。基于先前的发现,即4-(烷硫基)-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶是有效的抗球虫药,我们对该系列的鸡抗艾美拉虫进行了研究。在本研究中,活性最高的抗球虫药是4-环戊基氨基衍生物(8),该化合物能清除雏鸡饮食中200 ppm的寄生虫。该系列的某些成员在体外对胚胎鸡肝细胞,小鼠细胞和人细胞有毒性。4-二乙氨基衍生物(16)在体外无毒,似乎对雏鸡有毒。
  • Pyrazolo[3,4-d]pyrimidine ribonucleosides related to 2-aminoadenosine and isoguanosine: synthesis, deamination and tautomerism
    作者:Frank Seela、Kuiying Xu
    DOI:10.1039/b708736e
    日期:——
    than that of the related purines. The pK(a) values indicate that the 7-non-functionalized nucleosides 1a (pK(a) 5.8) and 15 (pK(a) 6.4) are possibly protonated in neutral conditions when incorporated into RNA. The nucleosides 3a-d exist predominantly in the keto (lactam) form with K(TAUT) (keto/enol) values of 400-1200 compared to 10(3)-10(4) for pyrrolo[2,3-d]pyrimidine isoguanosine derivatives 4a-c
    描述了与2-氨基腺苷和异鸟苷相关的8-氮杂-7-脱氮嘌呤(吡唑并[3,4-d]嘧啶)核糖核苷的合成和性质。在BF(3)存在下,将1-氮-乙酰基2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖与8-氮杂7-脱氮嘌呤-2,6-二胺5糖基化。 )x Et(2)O作为催化剂,得到N(8)异构体14(73%)和痕量的N(9)异构体13a(4.8%)。在相同的反应条件下,7-卤代8-氮杂-7-脱氮嘌呤-2,6-二胺6-8提供了热力学上更稳定的N(9)核苷13b-d作为唯一产物(53-70%)。因此,位置7的卤素将糖基化作用从N(8)转移到N(9)。通过2-氨基的重氮化将8-氮杂-7-脱氮嘌呤-4,6-二胺核糖核苷1a-d转化为异鸟苷衍生物3a-d。尽管化合物1a b。在7位(酶结合位点)不含氮,它们被腺苷脱氨酶脱氨;但是,它们的脱氨速度比相关嘌呤的速度要慢得多。pK(a)值表明,将7个非功能化核苷1a(pK(a)5
  • Nucleosides, 38 <sup>1)</sup> <b>The Ribonucleosides of Allopurinol</b>
    作者:Frieder W. Lichtenthaler、Eckehard Cuny
    DOI:10.1002/cber.19811140505
    日期:1981.5
    Of the various conceivable ribonucleosides of allopurinol, the N-1-, N-2-, and N-5-isomers (9c-11c) as well as the 1, 5-and 2,5-bis-ribosylated derivatives 6c and 7c have been prepared via stannic chloride-induced glycosylation of bis (trimethylsilyl)allopurinol 4 with acylated ribofuranoses (5). Trimethylsilyl triflate as catalyst in addition produced the O4-ribosylated isomer 8a. – The structures
    在别嘌呤醇的各种可能的核糖核苷中,N -1-,N -2-和N -5-异构体(9c-11c)以及1、5和2,5-双核糖基化衍生物6c和7c已经通过氯化锡诱导双(三甲基甲硅烷基)alalpurinol 4与酰化的呋喃核糖核酸酶的糖基化反应制备了(5)。三氟甲磺酸三甲基甲硅烷基酯作为催化剂还产生了O 4-核糖基化的异构体8a。–从UV,1 H和13 C NMR数据确定了产品的结构。–评估了它们的黄嘌呤氧化酶抑制活性。
  • Synthesis and biological activity of certain 3,4-disubstituted pyrazolo[3,4-d]pyrimidine nucleosides
    作者:Howard B. Cottam、Charles R. Petrie、Patricia A. McKernan、Richard J. Goebel、N. Kent Dalley、Richard B. Davidson、Roland K. Robins、Ganapathi R. Revankar
    DOI:10.1021/jm00375a006
    日期:1984.9
    A number of 3,4-disubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides were synthesized and tested for their biological activity. Glycosylation of persilylated as well as nonsilylated 3-bromoallopurinol with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (4) provided the key intermediate 3-bromo-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)-pyrazolo[3,4-d] pyrimidin-4(5H)-one (5a). Similar glycosylations
    合成了许多3,4-二取代的吡唑并[3,4-d]嘧啶核糖核苷,并对其生物学活性进行了测试。使用1-O-乙酰基2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖(4)对全硅烷基化的和未甲硅烷基化的3-溴代嘌呤醇进行糖基化,从而提供了关键的中间体3-溴代1-(2,3, 5-三-O-苯甲酰基-β-D-呋喃呋喃糖基)-吡唑并[3,4-d]嘧啶-4(5H)-一(5a)。3-氰基铝嘌呤醇和3-(甲硫基)铝嘌呤醇的类似糖基化提供了相应的受保护的N-1糖基衍生物(5b和5c)。这些核苷(5a-c)的脱苯甲酰化得到相应的3-溴-,3-氰基-和3-(甲硫基)alalpurinol核苷(6a-c)。根据光谱研究以及向别嘌呤醇核糖核苷的转化,确定了6a和6c的糖基化位点和异头构型,而6b的结构分配是通过单晶X射线分析得出的。5a和5b的常规官能团转化提供了许多新颖的3-取代的别嘌呤醇核苷,其中包括10a和18a-d。4-氨基-3-溴吡唑并[3
查看更多

同类化合物

别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 4-amino-3-bromo-6-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 8-aza-7-deaza-7-propynyladenosine 1-(β-D-ribofuranosyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-3-carboxy-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 4-amino-1-(α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 2-(5-Amino-4-iminopyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-carboxamidine 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-piperidino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4-methoxy-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran- 2-yl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidoate 4-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-3-carbonitrile 4-amino-1-(β-D-ribofuranosyl)-3-[2-(methoxycarbonyl)ethenyl]-1H-pyrazolo[3,4-d]pyrimidine 1-Pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine 4-Amino-1-pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 4-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidamide Methyl 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidate 1H-Pyrazolo[3, 4-amino-1-beta-D-ribofuranosyl-, hydrazide, hemihydrate 2-(Hydroxymethyl)-5-[4-(methylamino)pyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-beta-D-ribofuranosyl-4-methoxypyrazolo[3,4-d] pyrimidine 2-[4-(Dimethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 4-{[(4-Nitrophenyl)methyl]sulfanyl}-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidine 2-(4-Hydrazinylpyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol [5-[4-(Benzylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate 2-(Hydroxymethyl)-5-(4-prop-2-enylsulfanylpyrazolo[3,4-d]pyrimidin-1-yl)oxolane-3,4-diol N-Benzyl-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(Hydroxymethyl)-5-pyrazolo[3,4-d]pyrimidin-1-yloxolane-3,4-diol [5-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate [3,4-Diacetyloxy-5-(4-anilinopyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-Pentofuranosyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [3,4-Diacetyloxy-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 2-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-[4-(Hydroxyamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-(Hydroxymethyl)-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-[4-(aziridin-1-yl)pyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 1-(β-D-ribofuranosyl)-4,6-bis(chlorodifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-4,6-bis(difluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine